THERAPY DOSSIER · th-ee13e0436001

Insulin-like growth factor I (IGF-1) cream

Biologic · Biologic (topical IGF-1); not a discrete ChEMBL small molecule; no genuine topical IGF-1 trial identified

Evidence & regulatory context

Mechanism: Biologic (topical IGF-1); not a discrete ChEMBL small molecule; no genuine topical IGF-1 trial identified
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24604317 ↗2014Mixed findings

Use of insulin-like growth factor in the healing of open wounds in diabetic and non-diabetic rats.

RatWoundWistarMalen = 96 rats in six groups of 16, with 4 rats sampled per group…Topical1% and 3% IGF-1 creamStarted on the day of wounding

Model: 0.9 mm circular full-thickness punch skin wound in alloxan-induced diabetic and non-diabetic rats

Topical 1% and 3% IGF-1 cream accelerated macroscopic re-epithelialisation and significantly increased myofibroblast alpha-smooth muscle actin expression, but acute inflammatory parameters including vascular proliferation and leukocyte counts did not differ significantly between groups.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…